Events & Presentations

Ablynx organises webcasts for analysts and investors on the occasion of financial results publications and product specific news. In addition, the Company’s presentations at investor conferences are often webcasted and made available for the broader public.

Upcoming IR Events

No events currently exist in this section.

Recent IR Presentations

J.P. Morgan 2018 Healthcare Conference - presentation of 8 January
8-11 January 2018 - San Francisco (CA), USA

Click here to replay the webcast

pdf version of the presentation

Webcast - Additional data from the Phase III HERCULES study of caplacizumab in aTTP, following ASH late-breaking data
12 December 2017

Click here to replay the webcast

pdf version of the presentation

Jefferies 2017 London Healthcare Conference
15-16 November 2017 - London, UK

Click here to replay the webcast

pdf version of the presentation

Webcast presentation - Ablynx announced positive topline results from the Phase III HERCULES study with caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)
2 October 2017

Click here to replay the webcast

pdf version of the presentation

Annual BAML Healthcare Conference
13-15 September 2017 - London, UK

pdf version of the presentation

Ablynx announced its 2017 half year financial results with webcast
24 August 2017

Click here to replay the webcast

pdf version of the presentation

Webcast presentatie - vobarilizumab, a novel best-in-class anti-IL-6R drug candidate for the treatment of RA
20 oktober 2016

Click here to replay the webcast

pdf version of the presentation

Upcoming Scientific Events

25th Biennial International Congress on Thrombosis
23-26 May 2018 - Venice, Italy

Medical Biotechnology 2018
24-25 May 2018 - Gent, Belgium

27th PAGE (Population Approach Group in Europe) Annual Meeting
29 May-1 June 2018 - Montreux, Switzerland

Recent Scientific Presentations

"Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura", presented by Professor Marie Scully in the late-breaking abstracts session at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, USA
12 December 2017 - Atlanta (GA), USA

pdf version of the presentation

Poster "Results of a Phase 2b Study of Vobarilizumab, an Anti-Interleukin 6 Receptor Nanobody®, as Monotherapy in Patients with Moderate-to-Severe Rheumatoid Arthritis" presented at the European Congress of Rheumatology (EULAR)
14-17 June 2017 - Madrid, Spain

pdf version of the presentation

Presentation "Remission and Maintenance of Efficacy in a Phase 2b study of Vobarilizumab, an Anti-Interleukin 6 Receptor Nanobody®, in Patients with Moderate-to-Severe Rheumatoid Arthritis despite Treatment with Methotrexateat" presented at the European Congress of Rheumatology (EULAR)
14-17 June 2017 - Madrid, Spain

pdf version of the presentation

Poster "Impact of caplacizumab treatment on mortality and major thromboembolic events in acquired TTP: Phase II TITAN study results" presented at the 21st European Hemathology Association Congress
9 June 2016 - Copenhagen, Denmark

pdf version of the presentation